API
< Back to all clusters
[HEALTH] · Poland · 2 sources

started · updated

Poland: Migraine patients face barriers to modern treatment

Approximately 7 million people in Poland suffer from migraines, with up to 750,000 experiencing chronic migraines that impact their professional and social lives. While the B. 133 drug program provides modern therapy for chronic migraine, it currently only serves about 3,600 patients and lacks the capacity to meet total demand due to restrictive access and the inability to return to treatment after the observation period.

Experts, including Professor Alina Kułakowska, President of the Polish Neurological Society, suggest that implementing pharmacy reimbursement for these medications could resolve many access issues. Although treatment involves costs, specialists argue that untreated migraines generate significantly higher economic and social costs.

In a recent recommendation, the President of the Agency for Health Technology Assessment and Tariff System (AOTMiT) advised against the pharmacy reimbursement of Aquipta (atogepant) for adult chronic migraine prevention. The agency cited higher costs compared to existing B. 133 program drugs and potential difficulties in monitoring treatment through pharmacy channels. The estimated increase in National Health Fund (NFZ) spending for atogepant was projected at approximately 42.44 million PLN in the first year and 107.93 million PLN in the second year.

Entities

Agency for Health Technology Assessment and Tariff System · Alina Kułakowska · National Health Fund · Poland · Polish Neurological Society